|
Orthologous residues
|
|
EGFR (human): Y1016‑p, EGFR (mouse): Y1018‑p, EGFR (rat): Y1017‑p, EGFR (pig): Y1016‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
A431 (epithelial)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
EGF
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
intracellular localization, molecular association, regulation, receptor internalization, altered
|
|
Effect of modification (process):
endocytosis, altered
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
Grb2 (human)
|
SH2
|
Disrupts
|
molecular association, regulation
|
|
co-immunoprecipitation
|
|
SHP-2 (human)
|
SH2
|
Induces
|
molecular association, regulation
|
|
co-immunoprecipitation
|
|
SOS1 (human)
|
|
Induces
|
molecular association, regulation
|
|
co-immunoprecipitation
|
|
RASA1 (human)
|
SH2
|
Induces
|
molecular association, regulation
|
|
co-immunoprecipitation
|
|
